Vanguard Capital Management
CAPR icon

Vanguard Capital Management’s Capricor Therapeutics CAPR Stock Holding History

Vanguard Capital Management’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$55.3M Buy
2,297,674
+269,942
+13% +$8.18M ﹤0.01% 1887
2026
Q1 		$61.6M Buy
+2,027,732
New +$54M ﹤0.01% 1744

Other funds holding CAPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Vanguard Capital Management's CAPR Position: Q2 2026 in Review

Vanguard Capital Management increased its Capricor Therapeutics (CAPR) stake by 13% in Q2 2026, buying an estimated $8.18M and bringing the position to 2,297,674 shares worth $55.3M. The position accounts for ﹤0.01% of the portfolio, ranked #1887.

Vanguard Capital Management first reported a position in CAPR in Q1 2026 and has held it in 2 quarters since. The position peaked at $61.6M in Q1 2026. 169 funds tracked by Wall St. Rank hold CAPR as of Q2 2026.

  • Vanguard Capital Management held 2,297,674 shares of Capricor Therapeutics worth $55.3M as of Q2 2026.
  • Vanguard Capital Management bought 269,942 Capricor Therapeutics shares in Q2 2026, an estimated $8.18M.
  • Capricor Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #1887 holding.
  • Vanguard Capital Management first reported a position in Capricor Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Capital Management's Capricor Therapeutics position peaked at $61.6M in Q1 2026.
  • 169 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.